Weighted Average Number of Shares Outstanding, Diluted of Cidara Therapeutics, Inc. from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Cidara Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 30 Sep 2018 to 30 Sep 2025.
  • Cidara Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Sep 2025 was 26,882,366, a 312% increase year-over-year.
  • Cidara Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 6,349,631, a 45% increase from 2023.
  • Cidara Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 4,371,375, a 94% decline from 2022.
  • Cidara Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 69,857,698, a 33% increase from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Cidara Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 26,882,366 +20,352,255 +312% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 15,547,403 +10,983,631 +241% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 14,177,743 +9,639,961 +212% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 6,349,631 +1,978,256 +45% 01 Oct 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
Q3 2024 6,530,111 +2,015,730 +45% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 4,563,772 +57,959 +1.3% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 4,537,782 -521,732 -10% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 4,371,375 -65,486,323 -94% 01 Oct 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
Q3 2023 4,514,381 -84,078,187 -95% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 4,505,813 -64,627,887 -93% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 5,059,514 -63,078,602 -93% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 69,857,698 +17,404,246 +33% 01 Oct 2022 31 Dec 2022 10-K 22 Apr 2024 2023 FY
Q3 2022 88,592,568 +39,058,612 +79% 01 Jul 2022 30 Sep 2022 10-K 22 Apr 2024 2023 FY
Q2 2022 69,133,700 +9,810,480 +17% 01 Apr 2022 30 Jun 2022 10-K 22 Apr 2024 2023 FY
Q1 2022 68,138,116 +21,170,903 +45% 01 Jan 2022 31 Mar 2022 10-K 22 Apr 2024 2023 FY
Q4 2021 52,453,452 +10,896,102 +26% 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 49,533,956 +6,325,648 +15% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 59,323,220 +18,358,040 +45% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 46,967,213 +9,110,875 +24% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 41,557,350 +8,284,386 +25% 01 Oct 2020 31 Dec 2020 10-K 23 Mar 2023 2022 FY
Q3 2020 43,208,308 +3,401,170 +8.5% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 40,965,180 +13,178,372 +47% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 37,856,338 +10,126,361 +37% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 33,272,964 01 Oct 2019 31 Dec 2019 10-K 04 Mar 2020 2019 FY
Q3 2019 39,807,138 +12,101,666 +44% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 27,786,808 01 Apr 2019 30 Jun 2019 10-K 04 Mar 2020 2019 FY
Q1 2019 27,729,977 01 Jan 2019 31 Mar 2019 10-K 04 Mar 2020 2019 FY
Q3 2018 27,705,472 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3

Cidara Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 6,349,631 +1,978,256 +45% 01 Jan 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
2023 4,371,375 -65,486,323 -94% 01 Jan 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
2022 69,857,698 +17,404,246 +33% 01 Jan 2022 31 Dec 2022 10-K 22 Apr 2024 2023 FY
2021 52,453,452 +10,896,102 +26% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 41,557,350 +11,622,541 +39% 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2023 2022 FY
2019 29,934,809 01 Jan 2019 31 Dec 2019 10-K 07 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.